Arcutis Submits sNDA for Roflumilast Cream 0.3% (Zoryve) for Psoriasis in Children Down to Age 2
Arcutis Biotherapeutics, Inc. has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication roflumilast cream 0.3% (Zoryve) for the treatment of plaque psoriasis in children down to the age 2. If approved, roflumilast cream 0.3% would be the first and only topical PDE4 inhibitor treatment […]